简介：摘要：树脂是牙体修复的主要材料。近年来，随着纳米材料及修复技术的发展，越来越多的可用于直接充填、具有流动性的新型复合树脂问世。但临床医师对新一代的流动复合树脂尚了解不多。为使临床医师能够正确理解并掌握新一代流动树脂的临床应用，笔者对流动复合树脂的发展进行回顾，对新一代流动树脂的原理及特性进行简要阐述并探讨此医疗技术于牙体修复中的应用。

简介：【摘 要】目的：探讨牙体病治疗中光固化复合树脂的临床运用效果。方法：选取 2019年 2月 -2020年 2月间收入治疗牙体病病患作为本次的研究对象（共有 65例患者， 89颗牙），所有病患均给予光固化复合树脂进行治疗，统计患者的治疗效果情况。结果： 89颗患牙结果中，优良有 65颗，占总治疗牙齿的 73.03%，一般有 19颗，占总治疗牙齿的 21.35%，失败有 5颗，占总治疗牙齿的 5.62%。结论：牙体病治疗中使用光固化复合树脂的临床疗效佳，其美观度、牙龈咀嚼效果均较好，可被推广使用。

简介：【摘要】目的：探究RCD方案对多发性骨髓瘤的疗效。方法：随机筛选48例多发性骨髓瘤患者，掷骰子分组，24例为普通组，24例为实践组，前者行MPT方案治疗，后者行RCD方案（来那度胺+环磷酰胺+低剂量地塞米松）治疗，样本在2020年6月-2021年6月入选，检测生化指标，评估有效性。结果：治疗前所检测的M-蛋白、β2微球蛋白无差异，P>0.05。治疗后再次检测，两项蛋白指标在实践组比普通组低，P

简介：　　【摘 要】目的：探究他克莫司与环磷酰胺治疗狼疮性肾炎的的效果和用药不良反应率。方法：纳入观察对象 40例（均确诊为狼疮性肾炎）进行实验研究，研究时间从 2015年 3月直至 2019年 5月。采用随机分组法，将观察对象分为甲乙两组，甲组 20例患儿使用他克莫司治疗，乙组 20例患儿采取环磷酰胺治疗。观察对比两组患儿治疗效果、不良反应发生情况。结果：甲组中 1例患儿疗效不明显，另外 19例均有改善，总有效率 95%;乙组中 5例疗效不明显， 1例病情恶化，另外 14例病情改善，总有效率 70%，两组间进行比较后得到 P<0.05。治疗后随访观察到，甲组患儿 1例出现尿痛的不良反应，乙组中有 6例，两组不良反应发生率的差异显著（ P<0.05）。结论：狼疮性肾炎患儿在治疗过程中可应用他克莫司与环磷酰胺进行治疗，对比发现，他克莫司可以明显提升治疗的有效率，并且控制了患儿不良反应的出现，治疗安全性得到保障，临床应用效果理想，值得推广。  　　【关键词】他克莫司 ;环磷酰胺 ;狼疮性肾炎 ;效果 ;不良反应率  　 [Abstract] Objective: To explore the effect and adverse reaction rate of tacrolimus and cyclophosphamide in the treatment of lupus nephritis. Methods: 40 patients (all diagnosed as lupus nephritis) were included in the experimental study. The study period was from March 2015 to may 2019. The observation objects were randomly divided into two groups, group A (20 cases) was treated with tacrolimus, and group B (20 cases) was treated with cyclophosphamide. The treatment effect and adverse reactions of the two groups were observed and compared. Results: in group A, the curative effect of 1 case was not obvious, the other 19 cases were improved, the total effective rate was 95%; in group B, the curative effect was not obvious in 5 cases, 1 case was deteriorated, the other 14 cases were improved, the total effective rate was 70%, the comparison between the two groups showed that P < 0.05. After treatment, 1 case of adverse reactions occurred in group A and 6 cases in group B. There was a significant difference in the incidence of adverse reactions between the two groups (P < 0.05). Conclusion: tacrolimus and cyclophosphamide can be used in the treatment of children with lupus nephritis. Compared with cyclophosphamide, tacrolimus can significantly improve the efficiency of treatment, and control the occurrence of adverse reactions in children. The safety of treatment is guaranteed and the clinical application effect is ideal, which is worthy of promotion.